Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q2 2022 Results - Earnings Call Transcript

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET

Company Participants

Keri Mattox - Senior Vice President, Chief Communications and Administration Officer

Bryan Hanson - Chairman, President, and Chief Executive Officer

Suky Upadhyay - Executive Vice President and Chief Financial Officer

Ivan Tornos - Chief Operating Officer

Conference Call Participants

Rick Wise - Stifel Nicolaus

Pito Chickering - Deutsche Bank

Larry Biegelsen - Wells Fargo

Josh Jennings - Cowen & Company

Jayson Bedford - Raymond James

Kyle Rose - Canaccord Genuity

Jason Wittes - Loop Capital

Chris Pasquale - Nephron Research

Steven Lichtman - Oppenheimer & Company

Operator

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Second Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, August 2nd, 2022. Following today's presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Keri Mattox, Senior Vice President, Senior Vice President, Chief Communications and Administration Officer. Please go ahead.

Keri Mattox

Thank you, Operator, and good morning, everyone. I hope you are all well and safe. Welcome to Zimmer Biomet's second quarter 2022 earnings conference call. Joining me today are Bryan Hanson, our Chairman, President and CEO; EVP and CFO, Suky Upadhyay; and COO, Ivan Tornos.

Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please note we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements.

Additionally, the discussions on this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included within our Q2 earnings release, which can be found on our Web site, zimmerbiomet.com.

With that, I'll turn the call over to Bryan. Bryan?

Bryan Hanson

All right, great. Thanks, Keri, and thanks to all of you for joining us this morning for the call. We've got three sections for the call this morning. The first section, I'll talk briefly about our Q2 performance from an overall perspective, and how a combination of strong execution and COVID recovery have actually enabled us to revise our expectations up again for the full-year. And that's in the face of some pretty significant macro pressures, especially around FX. I'll also spend a few minutes talking about ZB Innovation, that's a primary contributor to our performance today, and certainly our performance in the future, so we want to make sure we touch upon that.